Journal of Clinical Immunology

, Volume 24, Issue 2, pp 107–114

IVIG for Autoimmune, Fibrosis, and Malignant Conditions: Our Experience with 200 Patients

Note

DOI: 10.1023/B:JOCI.0000019809.55787.ec

Cite this article as:
Shoenfeld, Y. & Krause, I. J Clin Immunol (2004) 24: 107. doi:10.1023/B:JOCI.0000019809.55787.ec

Abstract

Intravenous immunoglobulin (IVIG) is generated from the plasma of more than 10,000 healthy subjects. Originally IVIG was employed to supplement the missing Igs in subjects with immune-deficiencies. Later on it was given successfully to patients with autoimmune conditions, in some of which the benefits were confirmed by double blind studies (i.e. polymyositis), while in others remarkable case reports and series of patients have alluded to its beneficial effects. Especially when conventional therapies failed. Recently, due to multiple mechanisms, IVIG was found to be useful in reducing collagen deposition (i.e. scleroderma) and to prevent metastatic spread. When given properly (not more than 0.4 g/Kg. B.W. 5 day), side effects are minimal. Yet, its high price (>3,000 US $ per monthly course) precludes the application of IVIG more frequently.

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  1. 1.Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer and Sackler Faculty of MedicineTel-Aviv UniversityIsrael
  2. 2.Incumbent of the Laura Schwarz-Kipp, Chair for Research of Autoimmune DiseasesTel-Aviv UniversityIsrael